BIND Therapeutics Names Andrew Hirsch COO - Quick Facts

(RTTNews) - BIND Therapeutics, Inc. (BIND) Monday said it has appointed Andrew Hirsch as its new Chief Operating Officer with expanded responsibilities, including program and alliance management and oversight of BIND's Russian operations. Andrew will continue to serve as CFO.

Jeff Hrkach, formerly Senior Vice President, Technology Research and Development, has been promoted to Chief Technology Officer with responsibility for the Accurin pipeline and Medicinal Nanoengineering platform.

BIND has also elected Dan Koerwer, who was promoted to Senior Vice President of Business Development and Commercial in 2013, and Scott Minick, BIND's Chief Executive Officer.

Andrew Hirsch has been serving as BIND's Chief Financial Officer since July 2012, prior to which he was Vice President of Finance and CFO at Avila Therapeutics, Inc. He has also served in roles of increasing responsibility during his nearly ten-year tenure at Biogen Idec.

Jeff Hrkach previously served as BIND's Senior Vice President, Technology, R&D, since January 2010. Prior to that he was Vice President of Pharmaceutical Sciences.